

# Eleven-Year Summary of Selected Financial Data

	JPY millions										
	FY2010	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020
	JGAAP	JGAAP	JGAAP	IFRS	IFRS	IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
<b>For the year:</b>											
Net sales/Revenue	110,812	114,416	119,066	146,260	161,831	195,291	199,096	224,942	234,026	241,555	<b>249,605</b>
Cost of sales	34,437	35,385	41,501	57,353	56,373	72,829	74,966	86,378	90,764	94,831	<b>98,221</b>
Selling, general and administrative expenses <sup>1</sup>	32,415	35,073	36,164	41,642	48,893	59,406	62,193	68,788	71,273	73,360	<b>79,554</b>
Research and development expenses	13,221	17,225	16,719	16,862	17,477	19,990	22,786	24,398	23,759	23,341	<b>21,112</b>
Operating profit	30,739	26,733	24,681	29,878	35,374	80,180	32,479	38,691	45,098	33,535	<b>12,917</b>
Core operating profit	—	—	—	30,403	39,088	43,067	39,687	45,378	48,230	50,023	<b>50,101</b>
Income taxes/Income tax expenses	9,741	10,630	9,070	10,643	11,831	26,097	8,331	4,000	11,174	10,377	<b>5,773</b>
Net income/Net profit for the year	21,333	17,160	16,520	19,718	24,032	53,373	21,724	35,261	31,943	21,714	<b>6,645</b>
Core net profit for the year	—	—	—	19,813	25,948	29,163	29,125	33,458	36,092	35,894	<b>37,549</b>
Capital expenditures/Payments for acquisition of property, plant and equipment, and intangible assets	1,651	3,281	3,609	5,879	66,440	9,092	9,500	9,937	8,332	9,228	<b>23,804</b>
Depreciation and amortization	2,976	2,949	3,291	2,841	6,958	9,338	9,882	10,896	10,969	16,573	<b>16,768</b>
<b>At year-end:</b>											
Total assets	184,801	198,801	199,640	237,640	304,200	355,399	358,906	388,463	391,186	408,768	<b>402,353</b>
Net assets/Total equity	156,404	164,861	165,132	187,210	211,779	260,009	255,929	287,557	292,572	302,560	<b>307,050</b>
Liabilities	28,397	33,940	34,507	50,430	92,421	95,391	102,977	100,905	98,614	106,208	<b>95,303</b>
<b>Per share data (JPY):</b>											
EPS (Net income / Basic earnings) <sup>2</sup>	249.71	196.96	195.81	47.78	58.18	128.99	52.96	86.73	78.67	59.16	<b>17.09</b>
Core EPS <sup>2</sup>	—	—	—	48.01	62.82	70.48	70.99	82.29	88.89	90.00	<b>94.09</b>
Equity/Equity attributable to owners of the company <sup>2,3</sup>	1,793.15	1,887.81	1,998.44	452.43	511.14	627.78	628.09	702.54	728.97	758.50	<b>769.67</b>
Cash dividends, applicable to the period <sup>2</sup>	18.00	20.00	20.00	20.00	22.00	25.00	26.00	26.00	26.00	27.00	<b>28.00</b>

<sup>1</sup> Research and development expenses are excluded under JGAAP.

<sup>2</sup> The Company conducted a five-for-one share split of ordinary shares on the effective date of April 1, 2015. Per share data other than cash dividends applicable to the period for fiscal 2013 and the subsequent fiscal years are calculated under the assumption that the share split took effect at the beginning of fiscal 2013. Cash dividends applicable to the period have been retrospectively adjusted to reflect the impact of the share split.

<sup>3</sup> Equity is calculated by deducting stock subscription rights from net assets under JGAAP.

Financial Data

Eleven-Year Summary of Selected Financial Data

	JPY millions										
	FY2010	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020
	JGAAP	JGAAP	JGAAP	IFRS	IFRS	IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
<b>Cash flows:</b>											
Net cash flows from (used in) operating activities	17,768	21,483	9,942	26,686	25,386	22,525	10,843	42,843	32,894	39,947	<b>38,808</b>
Net cash flows from (used in) investing activities	(7,676)	(10,272)	(4,595)	(7,847)	(61,709)	37,052	(28,201)	(8,259)	(2,935)	(5,175)	<b>(53,355)</b>
Net cash flows from (used in) financing activities	(1,570)	(8,559)	(21,557)	(7,954)	28,960	(24,066)	(28,657)	(17,631)	(28,107)	(12,729)	<b>(16,685)</b>
Free cash flow <sup>1</sup>	16,118	18,203	6,334	20,807	(41,054)	13,433	1,342	32,906	24,562	30,719	<b>15,004</b>
Interest coverage ratio (times)	488.5	1,285.0	3,037.8	2,855.4	309.8	230.9	206.6	1,573.6	4,330.0	210.1	<b>244.6</b>
<b>Financial data:</b>											
ROE (Return (Net income) on equity/Return (Net profit for the year) on equity attributable to owners of the company) (%) <sup>2</sup>	14.5	10.7	10.0	11.1	12.0	22.6	8.4	13.0	11.1	8.0	<b>2.2</b>
Core ROE (%)	—	—	—	11.2	13.0	12.4	11.3	12.4	12.5	12.1	<b>12.3</b>
ROA (Return (Net income/Net profit for the year) on total assets) (%)	12.1	8.9	8.3	8.9	8.9	16.2	6.1	9.4	8.2	5.4	<b>1.6</b>
Equity ratio/Equity attributable to owners of the company ratio (%) <sup>2</sup>	84.5	82.8	82.6	78.8	69.6	73.2	71.1	73.6	74.4	74.1	<b>76.4</b>
Debt equity ratio (Interest-bearing debt to equity ratio/Interest-bearing debt to equity attributable to owners of the company ratio) (times) <sup>2</sup>	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.0	<b>0.0</b>
PER (Price earnings ratio) (times)	13.3	17.9	22.7	19.2	30.1	13.1	30.4	19.8	21.0	31.4	<b>89.1</b>
Dividend payout ratio (%)	36.0	50.8	51.1	41.9	37.8	19.4	49.1	30.0	33.0	45.6	<b>163.9</b>
Issued shares at fiscal year-end (thousands, including treasury shares)	87,053	87,147	82,469	82,583	82,653	414,192	406,173	406,848	399,782	400,028	<b>400,369</b>
Number of employees	2,867	3,053	3,050	3,072	3,230	3,463	3,667	3,805	4,073	4,108	<b>4,229</b>

<sup>1</sup> Free cash flow = Net cash flows from operating activities minus capital payments for acquisition of property, plant and equipment, and intangible assets

<sup>2</sup> Equity is calculated by deducting stock subscription rights from net assets under JGAAP.

# Main Financial Information

## Consolidated Statement of Profit or Loss and Other Comprehensive Income

Santen Pharmaceutical Co., Ltd. and Its Consolidated Subsidiaries

	JPY millions	
	FY2019	FY2020
Revenue	241,555	<b>249,605</b>
Cost of sales	(94,831)	<b>(98,221)</b>
<b>Gross profit</b>	146,724	<b>151,384</b>
Selling, general and administrative expenses	(73,360)	<b>(79,554)</b>
Research and development expenses	(23,341)	<b>(24,112)</b>
Amortization of intangible assets associated with products	(9,898)	<b>(9,920)</b>
Other income	390	<b>16,007</b>
Other expenses	(6,980)	<b>(40,889)</b>
<b>Operating profit</b>	33,535	<b>12,917</b>
Finance income	950	<b>1,346</b>
Finance expenses	(2,393)	<b>(1,488)</b>
Share of loss of investments accounted for using equity method	—	<b>(358)</b>
Profit before tax	32,091	<b>12,418</b>
Income tax expenses	(10,377)	<b>(5,773)</b>
<b>Net profit for the year</b>	21,714	<b>6,645</b>

### Other comprehensive income for the year

Items that will not be reclassified subsequently to profit or loss		
Remeasurements of defined benefit plans	(253)	<b>1,573</b>
Net gain or loss on financial assets measured at fair value through other comprehensive income	2,696	<b>45</b>
Items that may be reclassified subsequently to profit or loss		
Foreign currency translation adjustments	(3,972)	<b>7,116</b>
Other comprehensive income	(1,529)	<b>8,734</b>
<b>Total comprehensive income for the year</b>	20,185	<b>15,379</b>

### Profit attributable to

Owners of the company	23,618	<b>6,830</b>
Non-controlling interests	(1,904)	<b>(185)</b>
<b>Net profit for the year</b>	21,714	<b>6,645</b>

### Total comprehensive income attributable to

Owners of the company	22,162	<b>15,609</b>
Non-controlling interests	(1,977)	<b>(230)</b>
<b>Total comprehensive income for the year</b>	20,185	<b>15,379</b>

### Earnings per share (JPY)

Basic earnings per share	59.16	<b>17.09</b>
Diluted earnings per share	59.01	<b>17.06</b>

## Main Financial Information

### Consolidated Statement of Financial Position

Santen Pharmaceutical Co., Ltd. and Its Consolidated Subsidiaries (As of March 31)

	JPY millions	
	FY2019	FY2020
<b>Assets</b>		
<b>Non-current assets</b>		
Property, plant and equipment	35,601	<b>39,489</b>
Intangible assets	119,850	<b>112,876</b>
Financial assets	30,848	<b>31,903</b>
Retirement benefit asset	—	<b>1,619</b>
Investments to which equity method has been applied	—	<b>5,162</b>
Deferred tax assets	2,100	<b>2,824</b>
Other non-current assets	1,813	<b>2,249</b>
Total non-current assets	190,212	<b>196,122</b>
<b>Current assets</b>		
Inventories	35,282	<b>41,575</b>
Trade and other receivables	86,999	<b>95,992</b>
Other financial assets	452	<b>527</b>
Other current assets	4,392	<b>5,248</b>
Cash and cash equivalents	91,430	<b>62,888</b>
Total current assets	218,556	<b>206,231</b>
Total assets	408,768	<b>402,353</b>

### Equity

Equity attributable to owners of the company		
Share capital	8,366	<b>8,525</b>
Capital surplus	8,746	<b>8,954</b>
Treasury shares	(1,033)	<b>(934)</b>
Retained earnings	273,422	<b>270,757</b>
Other components of equity	13,364	<b>20,283</b>
Total equity attributable to owners of the company	302,865	<b>307,585</b>
Non-controlling interests	(305)	<b>(535)</b>
Total equity	302,560	<b>307,050</b>

### Liabilities

<b>Non-current liabilities</b>		
Financial liabilities	27,592	<b>10,141</b>
Net defined benefit liabilities	1,738	<b>1,210</b>
Provisions	570	<b>600</b>
Deferred tax liabilities	7,228	<b>3,290</b>
Other non-current liabilities	1,483	<b>1,514</b>
Total non-current liabilities	38,611	<b>16,754</b>
<b>Current liabilities</b>		
Trade and other payables	32,578	<b>38,106</b>
Other financial liabilities	18,777	<b>23,739</b>
Income tax payable	6,848	<b>5,458</b>
Provisions	633	<b>819</b>
Other current liabilities	8,761	<b>10,428</b>
Total current liabilities	67,597	<b>78,549</b>
Total liabilities	106,208	<b>95,303</b>
Total equity and liabilities	408,768	<b>402,353</b>

## Main Financial Information

## Consolidated Statement of Changes in Equity

Santen Pharmaceutical Co., Ltd. and Its Consolidated Subsidiaries (Fiscal 2019)

	JPY millions						JPY millions						
	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity		Other components of equity			Total equity attributable to owners of the company	Non-controlling interests	Total equity	
					Remeasurements of defined benefit plans	Net gain or loss on financial assets measured at fair value through other comprehensive income	Foreign currency translation adjustments	Subscription rights to shares	Total				
<b>Balance at April 1, 2019</b>	8,252	8,661	(1,131)	258,659	—	10,230	<b>Balance at April 1, 2019</b>	5,428	802	16,461	290,900	1,672	292,572
<b>Comprehensive income</b>							<b>Comprehensive income</b>						
Net profit for the year				23,618			Net profit for the year			—	23,618	(1,904)	21,714
Other comprehensive income					(253)	2,696	Other comprehensive income	(3,899)		(1,457)	(1,457)	(73)	(1,529)
Total comprehensive income for the year	—	—	—	23,618	(253)	2,696	Total comprehensive income for the year	(3,899)	—	(1,457)	22,162	(1,977)	20,185
<b>Transactions with owners</b>							<b>Transactions with owners</b>						
Issuance of new shares	114	114					Issuance of new shares		(117)	(117)	112		112
Acquisition of treasury shares			(22)				Acquisition of treasury shares			—	(22)		(22)
Retirement of treasury shares		(85)	121				Retirement of treasury shares			—	35		35
Dividends				(10,379)			Dividends			—	(10,379)		(10,379)
Share-based payments		56					Share-based payments			—	56		56
Other				1,523	253	(1,776)	Other			(1,523)	—		—
<b>Total transactions with owners</b>	114	85	99	(8,856)	253	(1,776)	<b>Total transactions with owners</b>	—	(117)	(1,640)	(10,198)	—	(10,198)
<b>Balance at March 31, 2020</b>	8,366	8,746	(1,033)	273,422	—	11,150	<b>Balance at March 31, 2020</b>	1,529	686	13,364	302,865	(305)	302,560

## Main Financial Information

## Consolidated Statement of Changes in Equity

Santen Pharmaceutical Co., Ltd. and Its Consolidated Subsidiaries (Fiscal 2020)

	JPY millions						JPY millions						
	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity		Other components of equity						
					Remeasurements of defined benefit plans	Net gain or loss on financial assets measured at fair value through other comprehensive income	Foreign currency translation adjustments	Subscription rights to shares	Total	Total equity attributable to owners of the company	Non-controlling interests	Total equity	
<b>Balance at April 1, 2020</b>	8,366	8,746	(1,033)	273,422	—	11,150	<b>Balance at April 1, 2020</b>	1,529	686	13,364	302,865	(305)	302,560
<b>Comprehensive income</b>							<b>Comprehensive income</b>						
Net profit for the year				6,830			Net profit for the year			—	6,830	(185)	6,645
Other comprehensive income					1,573	45	Other comprehensive income	7,161		8,778	8,778	(45)	8,734
Total comprehensive income for the year	—	—	—	6,830	1,573	45	Total comprehensive income for the year	7,161	—	8,778	15,609	(230)	15,379
<b>Transactions with owners</b>							<b>Transactions with owners</b>						
Issuance of new shares	160	160					Issuance of new shares		(167)	(167)	152		152
Acquisition of treasury shares			(4)				Acquisition of treasury shares			—	(4)		(4)
Retirement of treasury shares		(20)	102				Retirement of treasury shares			—	82		82
Dividends				(11,187)			Dividends			—	(11,187)		(11,187)
Share-based payments		68					Share-based payments			—	68		68
Other				1,692	(1,573)	(119)	Other			(1,692)	—		—
<b>Total transactions with owners</b>	160	208	98	(9,495)	(1,573)	(119)	<b>Total transactions with owners</b>	—	(167)	(1,859)	(10,888)	—	(10,888)
<b>Balance at March 31, 2021</b>	8,525	8,954	(934)	270,757	—	11,075	<b>Balance at March 31, 2021</b>	8,689	518	20,283	307,585	(535)	307,050

# Main Financial Information

## Consolidated Statement of Cash Flows

Santen Pharmaceutical Co., Ltd. and Its Consolidated Subsidiaries

JPY millions

	FY2019	FY2020
<b>Cash flows from operating activities</b>		
Net profit for the year	21,714	<b>6,645</b>
Depreciation and amortization	16,573	<b>16,768</b>
Impairment losses	5,825	<b>40,664</b>
Shares of loss (profit) of entities accounted for using equity method	—	<b>358</b>
Finance expenses (income)	(592)	<b>(609)</b>
Income tax expenses	10,377	<b>5,773</b>
Decrease (increase) in trade and other receivables	(3,054)	<b>(7,514)</b>
Decrease (increase) in inventories	(981)	<b>(4,590)</b>
Increase (decrease) in trade and other payables	717	<b>4,948</b>
Increase (decrease) in provisions and net defined benefit liabilities	(1,242)	<b>(176)</b>
Increase (decrease) in accounts payable—other	1,305	<b>3,199</b>
Increase (decrease) in long-term accounts payable—other	1,279	<b>(17,344)</b>
Other	1,584	<b>2,993</b>
Subtotal	53,506	<b>51,115</b>
Interest received	200	<b>195</b>
Dividends received	581	<b>490</b>
Interest paid	(190)	<b>(159)</b>
Income tax paid	(14,149)	<b>(12,834)</b>
Net cash flows from (used in) operating activities	39,947	<b>38,808</b>

## Cash flows from investing activities

Payments for acquisition of investments	(398)	<b>(3,384)</b>
Proceeds from sale of investments	3,503	<b>3,070</b>
Payments for acquisition of shares of subsidiaries	—	<b>(23,834)</b>
Payments for acquisition of investments accounted for using equity method	—	<b>(5,349)</b>
Payments for acquisition of property, plant and equipment	(5,824)	<b>(4,139)</b>
Payments for acquisition of intangible assets	(3,404)	<b>(19,665)</b>
Other	949	<b>(55)</b>
Net cash flows from (used in) investing activities	(5,175)	<b>(53,355)</b>

## Cash flows from financing activities

Proceeds from long-term loans	1,477	<b>307</b>
Repayments of long-term loans	(500)	<b>(3,000)</b>
Dividends paid	(10,379)	<b>(11,188)</b>
Repayments of lease obligations	(2,859)	<b>(2,952)</b>
Other	(469)	<b>148</b>
Net cash flows from (used in) financing activities	(12,729)	<b>(16,685)</b>
Net increase (decrease) in cash and cash equivalents	22,044	<b>(31,232)</b>
<b>Cash and cash equivalents at the beginning of year</b>	70,796	<b>91,430</b>
Effect of exchange rate changes on cash and cash equivalents	(1,410)	<b>2,690</b>
<b>Cash and cash equivalents at the end of period</b>	91,430	<b>62,888</b>